Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Nat Immunol. 2014 Oct 26;15(12):1134–1142. doi: 10.1038/ni.3028

Table 1.

Patient information.

Batch 1 Batch 2 Batch 3
IRAK4−/− P11, 9 male, age 12yo; Mutation: 1188+520A>G/1189- 1G>T; Splice mutation; on IVIG
P2 1, 9 male, age 12yo; Mutation: E402X/E402X; Nonsense mutation; on Cotrimoxazole
P3 1, 9 male, age 18yo; Mutation: Q293X/BAC210N13del; Nonsense mutation/large deletion; on Cotrimoxazole
P4 9 female, age 14yo; Mutation:Q293X/Q293X; Nonsense mutation; on Azythromycin and IVIG		 graphic file with name nihms634428t1.jpg graphic file with name nihms634428t2.jpg
MYD88−/− graphic file with name nihms634428t3.jpg graphic file with name nihms634428t4.jpg graphic file with name nihms634428t5.jpg
Controls 14 (6 for bacterial stimulation) 5 8 (2 young children)
Stimulations Toll-IL1R (PAM3, PAM2, PolyIC, Flagellin, LPS, R848, CpGs, IL1R, IL18R) + TNFa + PMAiono + 4 HK bacteria1 for IRAK-4P3, P4 and MyD88 P3, P4. Toll-R (PAM2, LPS) + TNFa + PMAiono + 4HK bacteria1 all patients Toll-R (PAM2, PAM3, PolyIC, R848) + PMAiono + 4HK bacteria1 + BCG + HSV + HK. CA all patients
*

siblings. In blue, patients reanalyzed in different batches to include new pathogen stimulations. IVIG: intravenous immunoglobulin.

1

4 HK bacteria include 3 strains of heat killed S. pneumoniae and S. aureus.